Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

400
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
400
Gene Therapy00:59

Gene Therapy

24.9K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
24.9K
Cancer Vaccines01:30

Cancer Vaccines

240
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
240

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of Novel Small-Molecule Inhibitors Targeting KDM5B and Evaluation of Their Antitumour Effects.

Cancer medicine·2026
Same author

Sequential supramolecular assembly of tannic acid and phenylboronic acid copolymers enabling enhanced cancer immunotherapy.

Journal of materials chemistry. B·2026
Same author

Simultaneous detection of multiple sdhB SNPs in Botrytis cinerea using a universal quenching probe-based LAMP assay.

Analytical sciences : the international journal of the Japan Society for Analytical Chemistry·2026
Same author

Whole-Exome Sequencing Analysis of a Young Obese Japanese Patient with Ketosis-Prone Diabetes: A Case Report.

Internal medicine (Tokyo, Japan)·2026
Same author

Prognostic Biomarkers and Immunotherapeutic Insights of Circulating Tumor DNA Analysis in Advanced Esophageal Squamous Cell Carcinoma From SCRUM-MONSTAR GOZILA Substudy.

JCO precision oncology·2026
Same author

High-Throughput Molecular Characterization of the Microbiome in Breast Implant-Associated Anaplastic Large Cell Lymphoma and Peri-Implant Benign Seromas.

Cancers·2025

Related Experiment Video

Updated: May 11, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

377

In Vivo Engineered CAR-T Cell Therapy: Lessons Built from COVID-19 mRNA Vaccines.

Sikun Meng1, Tomoaki Hara1, Yutaka Miura2

  • 1Department of Medical Data Science, Center of Medical Innovation and Translational Research, Osaka University Graduate School of Medicine, Yamadaoka 2-2, Suita, Osaka 565-0871, Japan.

International Journal of Molecular Sciences
|April 17, 2025
PubMed
Summary
This summary is machine-generated.

Messenger RNA (mRNA) and lipid nanoparticle (LNP) technologies offer new ways to improve chimeric antigen receptor T cell (CAR-T) therapy, especially for solid tumors. This approach aims to overcome current CAR-T limitations for better cancer treatment.

Keywords:
CAR-T therapyimmune response regulationlipid nanoparticlesmRNA technologymRNA vaccines

More Related Videos

Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models
06:22

Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models

Published on: February 2, 2024

3.2K
Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
06:18

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

2.3K

Related Experiment Videos

Last Updated: May 11, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

377
Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models
06:22

Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models

Published on: February 2, 2024

3.2K
Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
06:18

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

2.3K

Area of Science:

  • Oncology
  • Immunotherapy
  • Biotechnology
  • Molecular Medicine

Background:

  • Chimeric antigen receptor T cell (CAR-T) therapy has transformed cancer treatment but faces challenges like targeting solid tumors and ensuring cell persistence.
  • The success of mRNA vaccines and lipid nanoparticle (LNP) delivery systems during the COVID-19 pandemic showcases their potential for rapid development and efficient delivery.
  • These mRNA-LNP technologies present a novel framework to address existing limitations in CAR-T therapy.

Purpose of the Study:

  • To explore the application of mRNA-LNP technology for engineering CAR-T cells in vivo.
  • To identify strategies for overcoming current CAR-T therapy limitations, particularly in solid tumors.
  • To discuss future directions for enhancing CAR-T functionality and safety using mRNA-LNP advancements.

Main Methods:

  • Review of recent advancements in mRNA-based CAR engineering.
  • Analysis of optimized lipid nanoparticle (LNP) delivery systems for CAR-T therapy.
  • Exploration of strategies for improving in vivo CAR-T cell functionality and safety.

Main Results:

  • mRNA-LNP technology demonstrates potential for enhancing CAR-T efficacy, especially against solid tumors.
  • Recent advancements show promise in mRNA-based CAR engineering and LNP delivery for improved CAR-T function.
  • This approach could lead to more versatile and accessible CAR-T therapies.

Conclusions:

  • mRNA-LNP technology holds significant promise for advancing CAR-T therapy, addressing key challenges in solid tumor treatment.
  • Further development in mRNA design, LNP optimization, and in vivo engineering strategies is crucial.
  • This innovative approach could establish CAR-T therapy as a more adaptable and widely applicable cancer treatment.